Group 1: Company Performance - In 2022, the company achieved operating revenue of 422.78 million CNY, an increase of 8.69% year-on-year, and a net profit of 107.62 million CNY, up 14.49% year-on-year [5] - For Q1 2023, the company reported operating revenue of 106.95 million CNY, a growth of 14.87% compared to the same period last year, and a net profit of 24.99 million CNY, an increase of 2.57% year-on-year [7] Group 2: Market and Industry Insights - The pharmaceutical industry in China has maintained rapid growth, with total output value reaching 2.91 trillion CNY in 2022, reflecting a 20.10% increase in 2021 [7] - The ongoing healthcare reform and increased government spending on health are expected to provide new growth opportunities for the pharmaceutical market [7] Group 3: Product Competitiveness - The company’s core products include Sucralfate, Anacin, Atorvastatin Calcium, and PHBA, with competitive advantages in production technology and market recognition [3] - Atorvastatin Calcium production capacity has reached 100 tons, benefiting from a high market share due to downstream customer bidding [3] Group 4: Future Development Plans - The company aims to enhance its position in the raw materials and intermediates sector through continuous R&D and market promotion, aspiring to become a comprehensive pharmaceutical enterprise [4] - The company plans to further develop its advantageous products in international markets, particularly in high-end segments [2] Group 5: Investor Relations and Governance - The company emphasizes compliance and transparency in investor relations, planning to utilize various communication channels to engage with investors [4] - The board of directors is responsible for major decisions, while independent directors ensure compliance and protect shareholder interests [6]
海森药业(001367) - 投资者关系活动记录表